Posted by Michael Wonder on 20 Dec 2016
TGA approves new uses for Janssen's Imbruvica
20 December 2016 - The TGA has approved the use of ibrutinib for first-line use in patients with chronic lymphocytic leukaemia as well as for first and second-line use in patients with Waldenstrom’s macroglobulinaemia.
The TGA approved the extended use of ibrutinib on 15 December 2016 for the:
- Treatment of adult patients with Waldenstrom’s macroglobulinaemia who have received at least one prior therapy, or in first-line treatment of patients unsuitable for combination chemo-immunotherapy
- Adult patients with previously untreated CLL/SLL
